Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth
factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC) …

The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background Colorectal cancer (CRC) is one of the leading cause of cancer deaths
worldwide. Since CRC is largely asymptomatic until alarm features develop to advanced …

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with
chemotherapy is effective for patients with RAS wild type metastatic colorectal cancer …

Simple Summary Chemotherapy, radiotherapy and molecularly targeted therapy could
improve the prognosis of colorectal cancer (CRC) patients. Recently, immunotherapy …

Background. In metastatic colorectal cancer, mutation testing for KRAS exon 2 is widely
implemented to select patients with wild-type tumors for treatment with the monocloncal anti …

The discovery of mutant KRAS as a predictor of resistance to epidermal growth-factor
receptor (EGFR) monoclonal antibodies brought a major change in the treatment of …

Background: KRAS codons 12 and 13 mutations predict resistance to anti-EGFR
monoclonal antibodies (moAbs) in metastatic colorectal cancer. Also, BRAF V600E mutation …

Personalized cancer medicine based on the genetic milieu of individual colorectal tumors
has long been postulated, but until recently this concept was not supported by clinical …